Diabetic Kidney Disease
Conditions
Interventions
control group of early stage:basic treatment of western medicine
inducing heat group:western medicine and formula of inducing heat to eliminate mass
control group of middle stage:basic treatment
clearing heat group:basic treatment and formula of clearing heat therapy
control group of later stage:basic treatment
drain turbidity group:basic treatment and formula of draining turbidity
Sponsors
Dongzhimen Hospital,Beijing University of Chinese Medicine
Eligibility
Sex/Gender
All
Age
25 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Being diagnosed diabetic kidney disease, for those who it is difficult to exclude other kind of kindey disease, kindey biopsy is necessary; 2. Aged 25 to 75 years, male or female; 3. eGFR=30ml/min/1.73m2,have not received dialysis treatment; 4. for those with hypertesion, blood pressure should be control to less than 140/90mmHg, for elders the SBP should be less than150mmHg; 5. Glycated hemoglobin (HbA1c) should be less than 7.0%, for those with repeated hypoglycemia, life expectancy is short, or with significant microvascular or macrovascular complications, or other severe comorbidities and those who it isl difficult to achieve the standard requirements afterall kinds of therapyHbA1c should be less than =8%; 6. subjects must be informed details of the trail and sign the informed consent.
Exclusion criteria
Exclusion criteria: 1. Have severe infection or anemia, or electrolyte disorders, acute complications of diabetes in recent 4 weeks; 2. Have had serious heart, brain, liver or hemorrhage disease (like cerebral infarction, cerebral hemorrhage, transient ischemic attack, myocardial infarction, unstable angina, heart failureor result of ALT or AST is higher than 2 times of normal range; 3. use corticosteroids or immunosuppressants in recent 3 month; 4. oliguria or anuria, severe edema, massive pleural and peritoneal effusion; 5. have received renal transplantation; 6. Subjest with mental illness; 7. Women in gestational lactational period; 8. Allergic to the trial drugs; 9. Being enrolled to other clinical study; 10. not fully understand, reluctant to participant in, or do not sign informed consent.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 24 hours urinary protein quantitation;eGFR;Urinary albumin excretion rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| HbA1c;Scr;TCM syndrome;Quality of life; | — |
Countries
China
Contacts
Public ContactYaoxian Wang
Dongzhimen hospital, Beijing University of Chinese Medicine
Outcome results
None listed